Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Stock Information for Quince Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quince Therapeutics Inc.

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Quince Therapeutics to Present at Citizens Life Sciences Conference
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.